Koers Cosmo Pharmaceuticals S.p.A Swiss Exchange
Aandelen
IT0004167463
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- CHF | - |
Omzet 2023 | 96,72 mln. 105 mln. 94,63 mln. | Omzet 2024 * | 262 mln. 284 mln. 256 mln. | Marktkapitalisatie | 1,16 mld. 1,26 mld. 1,13 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | 1 mln. 1,08 mln. 978K | Nettowinst (verlies) 2024 * | 111 mln. 120 mln. 109 mln. | EV/omzet 2023 | 8,6 x |
Nettoliquiditeiten 2023 | 48,44 mln. 52,53 mln. 47,39 mln. | Nettoliquiditeiten 2024 * | 110 mln. 119 mln. 108 mln. | EV/omzet 2024 * | 4,01 x |
K/w-verhouding 2023 |
771
x | K/w-verhouding 2024 * |
9,93
x | Werknemers | - |
Dividendrendement 2023 |
3,65% | Dividendrendement 2024 * |
2,91% | Vrij verhandelbaar | 44,36% |
Recentste transcriptie over Cosmo Pharmaceuticals S.p.A
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01-06-16 |
Chairman | 61 | 01-01-06 | |
Chief Tech/Sci/R&D Officer | 54 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 69 | 01-01-97 | |
Director/Board Member | 69 | 01-04-12 | |
Chairman | 61 | 01-01-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,73% | 739 mld. | |
+32,83% | 598 mld. | |
-6,30% | 353 mld. | |
+15,15% | 318 mld. | |
+4,05% | 285 mld. | |
+15,00% | 240 mld. | |
-5,52% | 206 mld. | |
+6,17% | 164 mld. | |
-0,45% | 162 mld. |
- Beurs
- Aandelen
- Koers COPN
- Koers